Evotec and Bristol-Myers Squibb expand iPSC collaboration
Advertisement
Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases. This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very pleased about this latest expansion of our iPSC-alliance with Bristol-Myers Squibb. Patient-derived disease models will be instrumental to improving the translatability of pre-clinical discovery efforts into clinical benefits and we are proud to leverage our proprietary iPSC platform together with Bristol-Myers Squibb for the benefit of the patients.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Category:Inhalants
PolyTherics Receives Second Patent Allowance in Record Time
Artificial intelligence helps to find new natural substances - New method enables fast and confident identification of previously unknown small molecules
Eckert & Ziegler subsidiary IBt Bebig acquires specialist for medical planning software
Syngenta invests in Avidex
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type - Triggers US$ 9.0 m payment to Evotec
Immune Cells Also Attack Neurons Directly - New Findings on Multiple Sclerosis
Instant messaging in proteins discovered - Researchers unravel fundamental communication processes in proteins
Australian_and_New_Zealand_College_of_Anaesthetists
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
Symphogen: Patent for Polyclonal Antibody Compositions for Allergy Treatment
